AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
insight
/
details

Radiogenomics: a key component of precision cancer medicine

NextEdge Admin

25 Nov 2024

4 min 58 sec

genomic,precision cancer,Biomarkers,molecular

Radiogenomics is an emerging interdisciplinary field that integrates imaging data (radiology) with genomic information to advance precision cancer medicine. By correlating specific imaging features with genetic and molecular profiles of tumors, radiogenomics aims to provide deeper insights into cancer behavior, prognosis, and response to therapy. Here's how radiogenomics contributes to precision oncology:

1. Understanding Tumor Biology

Imaging Biomarkers: Radiogenomics identifies imaging biomarkers that correlate with molecular characteristics of tumors, such as mutations, gene expression patterns, and epigenetic changes. For example, specific MRI or CT features might indicate the presence of mutations like EGFR in lung cancer or IDH in gliomas.
Spatial Heterogeneity: While biopsy captures a limited sample of a tumor, imaging provides a non-invasive way to study the entire tumor and its microenvironment, revealing spatial heterogeneity and molecular gradients.

2. Predicting Treatment Response

Radiogenomics can predict how a tumor is likely to respond to treatments, such as chemotherapy, immunotherapy, or radiation therapy. Imaging-genomics associations help in tailoring therapy regimens based on individual tumor profiles.
For example, in brain tumors like glioblastomas, radiogenomic markers can help determine which patients may benefit from certain therapies or predict resistance mechanisms.

3. Prognostic Value

Radiogenomics allows clinicians to predict outcomes more accurately by linking imaging features to prognostic genomic signatures. For instance, tumors with aggressive genomic profiles often exhibit distinct imaging patterns, which can inform risk stratification.

4. Guiding Biopsies and Monitoring Disease

Radiogenomics helps target biopsies to the most clinically relevant regions of a tumor, minimizing the risk of missing aggressive or actionable components.
It facilitates longitudinal monitoring of tumor evolution through imaging, reducing the need for repeated invasive biopsies.

5. Advancing AI and Machine Learning

Radiogenomics relies on advanced computational techniques, including machine learning, to analyze large datasets of imaging and genomic data. These models can identify subtle patterns and correlations that are difficult to detect manually.

Challenges and Future Directions:

Data Integration: Combining high-dimensional imaging and genomic data requires robust computational frameworks and collaborative efforts.
Standardization: Standardizing imaging protocols and genomic assays is crucial for reproducibility across institutions.
Validation: Radiogenomic findings must be validated in large, diverse patient cohorts.
Ethics and Privacy: Handling sensitive genomic and imaging data requires adherence to strict privacy standards.

Clinical Applications:

Radiogenomics is already making an impact in cancers such as:

Brain Cancer: Correlating imaging phenotypes with mutations (e.g., IDH mutation, MGMT methylation) in gliomas.
Breast Cancer: Linking mammographic density and MRI features to gene expression profiles.
Lung Cancer: Predicting EGFR mutations and other driver alterations from CT imaging.
Prostate Cancer: Utilizing MRI to infer genomic markers like PTEN loss or TMPRSS2-ERG fusions.

In conclusion, radiogenomics bridges the gap between imaging and molecular oncology, enabling a more comprehensive understanding of cancer. As technology advances, it promises to refine diagnosis, improve therapeutic decisions, and enhance patient outcomes in precision cancer medicine.

Related Tags

Radiogenomics

genomic

precision cancer

Biomarkers

molecular

Pancreatic Cancer and Genomics: Revisiting Advances and Challenges

The Role of AI in Healthcare for Precision Care

Top Reviews

No reviews yet